Literature DB >> 8972892

The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients.

E Paran1, O Anson, L Neumann.   

Abstract

The aim was to evaluate the effects of a change of treatment from beta-blocker to captopril on the quality of life of hypertensive patients. One hundred forty-nine mild to moderate hypertensive patients who were being treated with beta-blockers were randomly assigned to receive captopril (12.5 to 50 mg twice daily), or to continue on beta-blocker treatment (atenolol: 25 to 100 mg once daily [n = 121], or propranolol, 10 to 80 mg twice daily [n = 12]). When required, 25 mg hydrochlorothiazide was added in each group. The patients were followed over periods ranging from 6 to 12 months. Blood pressure, treatment side effects, and quality of life were monitored. Blood pressure was equally well managed in both groups, though a lower level of treatment was required in the captopril group. The captopril treated patients exhibited favorable changes in several aspects of quality of life: sleep-related, gastrointestinal, and physical activity-related symptoms improved from baseline to end of follow-up. Drowsiness and the ability to concentrate significantly improved in the captopril group only (P <.01). Change in treatment from beta-blocker to captopril resulted in equally well controlled blood pressure on a lower drug dose. Moreover, the change to captopril had a positive impact on the quality of life.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972892     DOI: 10.1016/S0895-7061(96)00253-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Old antihypertensive agents-diuretics and beta-blockers: do we know how and in whom they lower blood pressure?

Authors:  D A Sica
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

2.  Relationship between Duration of Sleep and Hypertension in Adults: A Meta-Analysis.

Authors:  Yan Wang; Hao Mei; Yan-Rui Jiang; Wan-Qi Sun; Yuan-Jin Song; Shi-Jian Liu; Fan Jiang
Journal:  J Clin Sleep Med       Date:  2015-09-15       Impact factor: 4.062

Review 3.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

4.  Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.

Authors:  Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

Review 5.  Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess.

Authors:  Mauro Di Bari; Niccolò Marchionni; Marco Pahor
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension.

Authors:  Michael A Moore
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

Review 7.  Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis.

Authors:  Ana Célia Caetano de Souza; José Wicto Pereira Borges; Thereza Maria Magalhães Moreira
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

8.  A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285].

Authors:  Cornel Pater; Deepak Bhatnagar; Jean-Pascal Berrou; Joachim Luszick; Katrin Beckmann
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.